Vanda Pharmaceuticals (VNDA) : Analyst Rating Update

Vanda Pharmaceuticals (VNDA) : Zacks Investment Research ranks Vanda Pharmaceuticals (VNDA) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 3 research analysts is 1, which indicates as a Strong Buy.

Vanda Pharmaceuticals (VNDA) : Currently there are 3 street experts covering Vanda Pharmaceuticals (VNDA) stock. The most bullish and bearish price target for the stock is $20 and $15 respectively for the short term. The average price target of all the analysts comes to $17. The estimated standard deviation from the target is $2.65.

Vanda Pharmaceuticals (NASDAQ:VNDA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $11.47 and $11.32 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $11.65. The buying momentum continued till the end and the stock did not give up its gains. It closed at $11.65, notching a gain of 1.39% for the day. The total traded volume was 321,679 . The stock had closed at $11.49 on the previous day.

The company shares have dropped -1.37% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $14.50 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $10.63 and the 200 Day Moving Average price is recorded at $9.03.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Companys product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.